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Background: GINA guideline recommends stepping down treatment of asthma patients where
control is achieved.
The aim of this analysis was to estimate the costs and health outcomes associated with step
down of controlled patients on high dose fluticasone/salmeterol (FP/S 1000/100 mg daily) to
either medium dose FP/S (500/100 mg) dry powder or extrafine beclometasone/formoterol
(BDP/F 400/24 mg) pMDI in three European countries.
Methods: A patient-level simulation Markov model was constructed to enable the simulation of
three comparative arms (FP/S 1000/100, FP/S 500/100, BDP/F 400/24). Transition probabili-
ties and healthcare resources consumption were derived from a multinational clinical trial
comparing BDP/F 400/24 mg vs. FP/S 500/100 mg as step down therapy in asthma. Direct costs
and health state utilities were sourced from public source and published literature. The anal-
ysis was conducted from a health system perspective, based on six months horizon. Probabi-
listic sensitivity analyses were conducted.
Results: The ICER (Incremental Cost-Effectiveness Ratio) associated with high dose dry powder
FP/S 1000/100 mg vs. extrafine BDP/F 400/24 mg was above 70,000 GBP and 200,000 V/QALY
(Quality Adjusted Life Years). An ICER of 29,000 GBP/QALY and above 30,000 V/QALY was asso-
ciated with medium dose dry powder FP/S 500/100 mg vs. BDP/F 400/24 mg.
Conclusions: It was found that maintaining controlled patients on high dose FP/S is not cost-
effective. Extrafine BDP/F 400/24 mg daily can be considered to be a cost-effective option.com (L. Pradelli).
3 Elsevier Ltd. All rights reserved.
3.07.010
1532 P. Paggiaro et al.in the countries analyzed to maintain control of asthmatic patients stepped down from high
dose FP/S 1000/100 mg daily dry powder or suspension formulations.
ª 2013 Elsevier Ltd. All rights reserved.Figure 1 Graphic representation of Markov model structure.
Two arms are collapsed for graphical convenience; their
structure is identical to the fully represented arm.Introduction
There has been a rapid increase in the cost of healthcare,
driven by new technologies and an ageing population. This
is a challenge that all industrialized societies are facing [1].
European pharmaceutical expenditure has increased
steeply in recent years, rising between 4% and 13%
(approx.) year on year [2] and is now one of the largest cost
components across a number of European countries [2e7].
As a result, almost all European countries have intro-
duced cost containment measures aimed directly or indi-
rectly at limiting the growth of healthcare expenditure [8].
Given that approximately 30 million adults in Europe have
asthma [9], identifying cost-effective therapeutic strategies
to treat adult asthma is important as the disease imposes a
severe economic burden on society [10e13]. According to
GINA (Global INitiative for Asthma) [14] asthma control is
achieving and maintaining control of symptoms and normal
daily activity, maintaining pulmonary function as close to
normal as possible, preventing asthma exacerbations and
avoiding adverse effects from asthma medication. The
stepwise approach is to gain control, sustain control and
then to “step down” treatment to the minimum amount of
medication necessary to maintain asthma control, avoiding
unnecessarily high drug exposures and the potential associ-
ated long-term side effects [14e16].
Ongoing monitoring is essential to assess that control is
maintained for a prolonged period (at least 3 months)
before “step down” is considered [14]. Although “step-
down” is recommended [14,17], it has been previously re-
ported that controlled asthma patients appear to be left
overtreated on high dose ICS [18].
Few studies evaluated treatment step-down from a high
dose to a lower dose ICS/LABA combination [15,19], and
only one such study has assessed it with different drug
formulations [15].
As discussed above, the growing economic pressures
within healthcare systems mean that an efficient use of
health-care resources is warranted, in which both health
and economic outcomes of treatments are assessed [20].
The aim of this analysis was to estimate the costs and
health outcomes associated with “step down” of patients
controlled on high dose fluticasone/salmeterol (FP/S 1000/
100 mg daily) to either extrafine beclometasone/formoterol
(BDP/F 400/24 mg) pMDI or medium dose FP/S (500/100 mg)
dry powder in three western European countries.
Methods
Study design
A recent clinical trial [15] provides evidence confirming
that lung function and asthma control can be maintained in
patients stepped down from the highest recommendeddose of ICS/LABA combination therapy to extra-fine
beclomethasone/formoterol treatment. In a prospective,
multinational, randomized, open label, parallel group
controlled trial, patients with controlled asthma treated
daily with high dose (1000/100 mg) fluticasone/salmeterol
(FP/S) Diskus were randomly assigned to 24 weeks of
treatment with either FP/P Diskus 500/100 mg daily or BDP/
F pMDI 400/24 mg daily.
Based on clinical outcomes and resource consumption
data from the trial, a Markov decision model (Fig. 1) was
constructed in TreeAge Pro 2009 to analyze cost and cost-
effectiveness of high dose FP/S 1000/100 mg, medium dose
FP/S 500/100 mg and BDP/F 400/24 mg for three European
countries (United Kingdom, Spain and the Netherlands). In
a probabilistic patient-level health economics Markov
model, the individual experience is represented by
defining his/her possible health states and the probability
of transiting from one to the others in a given time unit.
The permanence in any given state and/or the transition
from one to another is associated with a set of clinical and
economic outcomes. In the present model, the three GINA
e defined [14] control levels were used to characterize
patients health states in the clinical trial and for the
simulation, namely Controlled, Partly Controlled and Un-
controlled; the time unit is four weeks, and the applied
transition probabilities have been calculated to reflect the
monthly rates of patients loosing/gaining control, as
observed in the FORTE trial.
Variability is a characteristic feature of asthma and
achieving GINA defined asthma control maybe challenging
in clinical practice. It has been reported that patients may
adopt a lifestyle to ensure fewer symptoms at the expense
of limiting daily activities [21]. Therefore, both partially
controlled and controlled asthma may sometimes be
acceptable health states in clinical practice, and they have
been aggregated in the model.
Health conditions of the simulated patients were char-
acterized by a set of individual parameters attributed at
each state of the Markov model. These parameters were:
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- days with daytime symptoms in 4 weeks;
- days with nocturnal symptoms in 4 weeks;
- days with use of rescue treatments in 4 weeks;
- average PEF (peak expiratory flow, measured as % of
predicted).
These parameters were extracted from distributions
fitted to the data recorded in the trial on the ITT popu-
lation (Table 1). In the model, the determination of
the occurrence of an event in each cycle depended
on a binomial distribution for each parameter
(except the PEF value, which is sampled from a normal
distribution). For patients with a “yes” determination,
the number of events was extracted from a gamma
distribution.
Data from the 8-weeks run-in phase was used to build
the FP/S 1000/100 mg arm of the model, while the 24-
weeks data from patients randomized to BDP/F 400/24 mg
or to FP/S 500/100 mg were used to feed the two
respective arms. The database containing the asthma
control status at each visit for each patient in the
Intention To Treat (ITT) population was analyzed. Overall
378, 174 and 164 patients in treatment with FP/S 1000/
100 mg, FP/S 500/100 mg and BDP/F 400/24 mg were
considered, respectively. Since the run-in phase lasted
only for 8 weeks, the last observed value was carried
forward in the assumption of stable asthma control for
the next 16 weeks in the FP/S 1000/100 mg arm of the
model [15].
It was chosen to calculate outcomes in terms of addi-
tional QALY (Quality Adjusted Life Years). Utilities for each
asthma control state were derived from a study by Briggs
et al. [29].
The time frame of the model is the clinical trial period of
24 weeks, divided into 4-weeks cycles for the simulation,
according to the visit schedule of the trial.
Economic analysis
The chosen perspective is the payers’ perspective in all
countries analyzed. The cost input parameters include
medical costs and outpatient physician care (Table 2). Unit
costs are reported in 2011 V (Spain and the Netherlands)
and GBP (United Kingdom)Table 1 Frequencies and mean numbers of events recorded in
Parameter
%With at least 1 exacerbation in 4 weeks
Mean (SD) exacerbations/4 weeks
%With at least 1 day with daytime symptoms in 4 weeks
Mean (SD) days with daytime symptoms/4 weeks
%With at least 1 day with nocturnal symptom in 4 weeks
%With at least 1 day with rescue treatment in 4 weeks
Mean (SD) rescue treatment days/4 weeks
Mean (SD) PEF (% of predicted) in 4 weeks
SD: Standard deviation; CPC: controlled/partly controlled; U: uncont
model simulation.The outpatient care costs, i.e. office-based general
practitioner consult, were based on literature [22e24].
Drug prices are based on local price databases collected
between June and August 2011, including VAT and patients’
copayments (where they exist).
Test treatment costs were calculated according to the
pharmaceutical form and contents used in the trial. Drug
prices were derived from formulary drugs, specific to each
country.
As controlled asthma is generally monitored by general
practitioners (GP), in the model it was assumed that pa-
tients attend the GP once per quarter, independently from
the patient’s state.
In the trial no exacerbation gave rise to emergency
consultations or to hospitalizations. Consequently, addi-
tional consumption of these resources for patients experi-
encing exacerbations were not added. On the other hand,
the trial population attended every 4 weeks a physician
visit and it’s reasonable to hypothesize that in real prac-
tice, where asthma control assessments are not so
frequent, the patient is more likely to request health care
in case of exacerbation, a consideration consistent with
GINA guidelines, that recommend the attending of a health
care visit within two weeks to one month after an exacer-
bation [14]. Based on this, the management of an exacer-
bation was linked to the cost of a general practitioner visit.
The study protocol allowed the use of inhaled salbutamol as
on demand medication; in the model the cost of rescue
medications was estimated based on the mean number of
days with salbutamol use, according to patient’s state.
Similarly, the control state-specific cost of concomitant
medications was estimated based on the drug consumptions
recorded at follow-up visits.
Simulation: base case and probabilistic sensitivity
analysis
In all cost-effectiveness models, it is important to test for
sensitivity to assumptions and uncertainties in the data
[30]. The present probabilistic simulation is performed at
patient-level, by drawing parameter values from their
probability distribution for each simulated individual
(conditioned on the asthma control state he/she is assigned
to), which enables two levels of uncertainty to be taken
into account:the trial by asthma control state.
CPC U TDF
1.57% 42.16% Binomial
1.91 (1.94) 1.35 (0.81) Gamma
33.4% 73.0% Binomial
3.47 (3.70) 9.99 (7.73) Gamma
8.4% 62.0% Binomial
35.3% 81.0% Binomial
4.12 (6.08) 13.54 (10.95) Gamma
98.77 (20.07) 88.23 (17.03) Normal
rolled, TDF: type of distribution fitted to the data and used for
Table 3 Simulation results.
BDP/F
400/24
FP/S
1000/100
FP/S
500/100
Controlled state
(days)
160 161 162
D vs. BDP/F e 1.22 2.27
QALYs 0.3884 0.3890 0.3896
D vs. BDP/F e 0.0006 0.0012
ICER vs. BDP/F
UK (£/QALY) e 72,441 29,826
Spain (V/QALY) e 295,319 44,780
Netherlands (V/QALY) e 227,801 33,364
Table 2 Cost inputs.
Country Resource Sources
Treatment acquisition (4 weeks)
High FP/S Medium FP/S BDP/F
UK (£) 38.08 32.76 27.44 [25]
Spain (V) 77.49 57.42 48.09 [26]
Netherlands (V) 58.19 42.49 35.49 [27]
GP consultation (unit)
UK (£) 13.07 [22,28]
Spain (V) 32.91 [24,28]
Netherlands (V) 28.37 [25,28]
Mean (SD) cost for concomitant and rescue medications (4 weeks)
Concomitant drugs Rescue medications
CPC U CPC U
UK (£) 1.21 (8.38) 1.61 (6.62) 0.02 (0.06) 0.16 (0.17) [25]
Spain (V) 1.33 (17.86) 1.79 (8.10) 0.04 (0.13) 0.34 (0.35) [26]
Netherlands (V) 0.72 (5.03) 2.14 (8.74) 0.07 (0.19) 0.51 (0.53) [27]
GP: General practitioner; SD: standard deviation; CPC: controlled-partly controlled; U: uncontrolled.
1534 P. Paggiaro et al. The uncertainty on patient characteristics, which rep-
resents the effective heterogeneity among subjects;
 The intrinsic uncertainty of events (even when the rate
of occurrence of a given event is perfectly known in a
population, it is not possible to know if the event will
actually occur in any individual belonging to that
population).
A third order of uncertainty, related to the input data
used for model parameters representing the cognitive un-
certainty on values derived from experimental measure-
ments, can be evaluated through the probabilistic
sensitivity analysis (PSA) [30].
In simulating the presented model, distributions related
to clinical outcomes and quality of life were sampled at the
patient-level, while distributions accounting for were
sampled at the cohort level, in the PSA external loop.
The single outcomes of the patient-level iterations (each
one representing a simulated patient) provide the base-
case results of the analysis, and reflect the inter-individual
variability in outcomes. The PSA provides an evaluation of
the uncertainty surrounding the mean (cohort-level) results
which is due to the uncertainty on collected mean costs and
resource consumption rates.
Base-case results were obtained with 10,000 iterations;
the PSA with 1000 (external loop)  1000 (internal loop)
iterations.
Results
Estimated QALYs show very similar values across treatments
and the increments of high and medium dose FP/S vs. BDP/
F are very close to 0 (Table 3).
In contrast, the total costs varied significantly between
treatments, mainly reflecting differences in drug acquisi-
tion costs, as concomitant medication and other direct
medical costs were similar (Fig. 2).Table 3 reports the mean incremental cost-effectiveness
ratios calculated for high and medium dose FP/S vs. BDP/F.
An additional analysis was carried out for the UK to
consider a different formulation of FP/S, consisting in a
pressurized metered dose inhaler (pMDI) with packages
containing 120 inhalation doses of 250/25 mg (£59.48) and
of 125/25 mg (£35.00), respectively for the high and the
medium requested dosages. The resulting ICERs for this
analysis were 192,166 £/QALY and 29,826 £/QALY.
Results of the PSA for the UK, the Netherlands, and Spain
are represented as scatter plots on the cost-utility plane,
where the grade of dispersion of the cloud can provide a
visual indication of the stability of the model, and as cost/
effectiveness acceptability curves in Fig. 3.
Discussion
Decision makers responsible for optimizing health gains
from finite resources are increasingly relying on an
evidence-based approach involving a cost-effectiveness
analysis. The measure most widely employed in such an
analysis is the ICER [31].
Figure 2 Simulation results: total cost by treatment and country.
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countries, acceptability at 30,000 V per QALY and
25,000 GBP per QALY gained [32] was considered. This was a
conservative approach as it is known that, for example, the
UK Health Technology Assessment body (NICE), would need
special reasons to accept technologies with ratios over
25,000 to 35,000 GBP per QALY [33].
Costs and outcomes of high dose FP/S (1000/100 mg
daily), extrafine BDP/F (400/24 mg) pMDI and medium dose
FP/S (500/100 mg) dry powder were compared. In the UK,
where there is a strong preference for pMDI devices, in
contrast to most other countries in Europe, an extra cost-
effectiveness analysis was done using medium dose FP/SFigure 3 Scatterplots of the incremental costs and benefits (QALY
cost-effectiveness acceptability curves (CEACs), in the UK, Netherla
400/24 mg Green line and dots: FP/S 500/100 mg vs. BDP/F 400/24
legend, the reader is referred to the web version of this article.)pMDI. The cost-effectiveness analyses showed that high
dose FP/S and medium dose FP/S were not cost-effective
options when compared to medium dose BDP/F (400/
24 mg), with a less than 1% probability of being cost-
effective, when the 25,000 GBP/QALY and 30,000 V/QALY
thresholds are used.
Conversely, medium dose FP/S had a probability of
being cost-effective above 50% only with a willingness
to pay (WTP) threshold of 39,000 and 50,000 V/QALY in
the Netherlands and Spain, or of 28,000 GBP/QALY.
Corresponding WTP threshold figures for high dose FP/S
were 162,000 and 210,000 V/QALY and of 78,000 GBP/
QALY.) vs. BDP/F 400/24 mg on the cost-effectiveness plane (top) and
nds, and Spain. Blue line and dots: FP/S 1000/100 mg vs. BDP/F
mg. (For interpretation of the references to color in this figure
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tween treatments, this was expected, as the analysis was
based on an equivalence clinical trial involving controlled
asthma patients.
Ideally, it would have been interesting to evaluate the
cost/effectiveness of the minimal effective dose. Two main
reasons prevented us to do so: firstly, as discussed in the
publication of the clinical trial results, the study design
prevented the researches from determining this dose level;
and secondly, we could not uncouple the efficacy data used
in the modeling from the doses which attained that level of
efficacy.
In contrast, the incremental total costs between treat-
ments (numerator) showed notable values.
The length of the clinical study period may be consid-
ered as a draw-back, because ideally the time horizon
would be longer than six months for patients with this
chronic disease. However, a limit to the time horizon of the
economic analysis was applied to avoid further effective-
ness assumptions for the medium term. Moreover, asthma is
not a progressive disease and the study recruited patients
over a 2-year period therefore including periods with known
triggers of asthma symptoms such as allergens (spring) and
viruses (winter).
In common with all economic models, a number of as-
sumptions have been made. The multinational setting of the
trial determined the need to modify the cost of drugs pre-
scribed in other countries by imposing the relevant prices
from each country concerned. The number of unscheduled
visits to general practitioners is often difficult to determine
and therefore the number of exacerbations was used as a
proxy. The cost of hospitalization due to exacerbations was
not included as no hospitalizations were reported during the
trial [15]. This may underestimate a rare but relevant event,
especially when looking at a longer time horizon. However,
given that the study population was controlled asthma pa-
tients, where control was being maintained following step-
down, the occurrence of hospitalization may have been
observed during a longer time horizon.
Another possible criticism of this analysis is that health
related quality of life was not assessed during the trial.
Hence, the utility attached to each health state had to be
derived from published literature [29]. This is often done
and it is well accepted in health economics, but ideally it is
advisable to collect health related quality of life data
during the trial to obtain more reliable results.
Classical double dummy double blind RCTs tend to limit
generalizability to usual clinical practice [34]. In the case of
the randomized control trial upon which the model is
based, the trial was an open label study, making it partly
pragmatic in terms of trial design [35]. This encourages
healthcare resource utilization more similar to actual
clinical practice [34]
All in all, despite the limitations discussed, this study
provides a useful analysis for decision makers and pre-
scribers wanting to adopt cost-effective treatment options.
Furthermore, if possible, future clinical work should
attempt to phenotype those patients who are likely to
remain stable following step-down, permitting refined tar-
geting of such a strategy. This would allow even greater
cost-savings while maintaining asthma control for an even
greater part of the population.Conclusion
The present study shows that maintaining controlled pa-
tients on high dose FP/S is not cost-effective in the
Netherlands, Spain and the UK. Furthermore, stepping pa-
tients down to medium dose FP/S was shown not to be cost-
effective relative to stepping down to BDP/F. Extrafine
BDP/F 400/24 mg daily can be considered to be an effective
and cost-saving option in the countries analyzed to main-
tain control of asthmatic patients stepped down from high
dose FP/S 1000/100 mg daily.
Given the stretched healthcare resources in the coun-
tries concerned and the current economic climate, step-
down to extrafine BDP/F offers a proven, evidence-based
therapeutic option that provides economic value to manage
controlled patients on high dose FP/S that are in need of
step down in accordance with clinical guidelines.
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